Machine learning, pharmacogenomics, and clinical psychiatry: predicting antidepressant response in patients with major depressive disorder

References

• GBD. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858.
   Google Scholar
• Bromet E, Andrade LH, Swang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9(1):90.
   Google Scholar
• Murray CJ, Lopez AD. Global morality, disability, and the contribution of risk factors: global burden of disease study. Lancet. 1997;349(9063):1436–1442.
   Google Scholar
• World Health Organization (WHO). The global burden of disease: 2004 update. [cited 2021 Mar 9]. Available from: https://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf?ua=1.
   Google Scholar
• Friedrich MJ. Depression is the leading cause of disability around the world. JAMA. 2017;317:1517.
   Google Scholar
• Liu Q, He H, Yang J, et al. Changes in the global burden of depression from 1990 to 2017: findings from the global burden of disease study. J Psychiatr Res. 2020;126:134–140.
   Google Scholar
• Smith K. Mental health: a world of depression. Nature. 2014;515(7526):181.
   Google Scholar
• Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655–679.
   Google Scholar
• Greenberg PE, Fournier -A-A, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(2):155–162.
   Google Scholar
• Otte C, Gold SM, Penninx BW, et al. Major depressive disorder. Nat Rev Dis Primers. 2016;2(1):160–165.
   Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917.
   Google Scholar
• Zimmerman M, McGlinchey JB, Posternak MA, et al. How should remission from depression be defined? The depressed patient’s perspective. Am J Psychiatry 2006;163:148–150.
   Google Scholar
• Blier P. Optimal use of antidepressants: when to act? J Psychiatry Neurosci. 2009;34(1):80.
   Google Scholar
• Perlis RH. Abandoning personalization to get to precision in the pharmacotherapy of depression. World Psychiatry. 2016;15(3):228–235.
   Google Scholar
• Gillett G, Tomlinson A, Efthimiou O, et al. Predicting treatment effects in unipolar depression: a meta-review. Pharmacol Ther. 2020;212:107557.
   Google Scholar
• Fava M, Uebelacker LA, Alpert JE, et al. Major depressive subtypes and treatment response. Biol Psychiatry. 1997;42(7):568–576.
   Google Scholar
• Parker G, Wilhelm K, Mitchell P, et al. Subtyping depression: testing algorithms and identification of a tiered model. J Nerv Ment Dis. 1999;187(10):610–617.
   Google Scholar
• Arnow BA, Blasey C, Williams LM, et al. Depression subtypes in predicting antidepressant response: a report from the iSPOT-D trial. Am J Psychiatry. 2015;172(8):743–750.
   Google Scholar
• Perlman K, Benrimoh D, Israel S, et al. A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder. J Affect Disord. 2019;243:503–515.
   Google Scholar
• Lee Y, Ragguett RM, Mansur RB, et al. Applications of machine learning algorithms to predict therapeutic outcomes in depression: a meta-analysis and a systematic review. J Affect Disord. 2018;241:519–532.
   Google Scholar
• Saveanu RV, Nemeroff CB. Etiology of depression: genetic and environmental factors. Psychiatr Clin North Am. 2012;35(1):51–71.
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, DC, USA: American Psychiatric Association; 2013.
   Google Scholar
• Zimmerman M, Ellison W, Young D, et al. How many different ways do patients meeting diagnostic criteria for major depressive disorder? Compr Psychiatry. 2015;56:29–34.
   Google Scholar
• Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med. 2013;11(1):126.
   Google Scholar
• Milaneschi Y, Lamers F, Peyrot WJ, et al. Polygenetic dissection of major depression clinical heterogeneity. Mol Psychiatry. 2016;21(4):516–522.
   Google Scholar
• Athreya A, Iyer R, Wang L, et al. Integration of machine learning and pharmacogenomic biomarkers for predicting response to antidepressant treatment: can computation all intelligence be used to augment clinical assessments? Pharmacogenomics. 2019;20(14):983–988.
   Google Scholar
• Carter GC, Cantrell RA, Zarotsky V, et al. COMPREHENSIVE REVIEW OF FACTORS IMPLICATED IN THE HETEROGENEITY OF RESPONSE IN DEPRESSION. Depress Anxiety. 2012;29(4):340–354.
   Google Scholar
• Dwyer DB, Falkai P, Koutsouleris N. Machine learning approaches for clinical psychology and psychiatry. Annu Rev Psychology. 2018;14(1):91–118
   Google Scholar
• Feczko E, Miranda-Dominguez O, Marr M, et al. The heterogeneity problem: approaches to identify psychiatric subtypes. Trends Cogn Sci. 2019;23(7):584–601.
   Google Scholar
• James G, Witten D, Hastie T, et al. An introduction to statistical learning. Vol. 112. 18.
   Google Scholar
• Doupe P, Faghmous J, Basu S. Machine learning for health services researchers. Value Health. 2019;22(7):808–815.
   Google Scholar
• Lin E, Lin C-H, Lane H-Y. Machine learning and deep learning for the pharmacogenomics of antidepressant treatments. Clin Psychopharmacol Neurosci. 2021;19(4):577–588.
   Google Scholar
• Tai AMY, Albuquerque A, Carmona NE, et al. Machine learning and big data: implications for disease modeling and a therapeutic discovery in the psychiatry. Artif Intell Med. 2019;99:101704.
   Google Scholar
• Bagby RM, Ryder AG, Cristi C. Psychosocial and clinical predictors of response to pharmacotherapy for depression. Journal of psychiatry & neuroscience: JPN. 2002;27(4):250–257.
   Google Scholar
• Chekroud AM, Zotti RJ, Shehzad Z, et al. Cross‐trial prediction of treatment outcome in depression: a machine learning approach. Lancet Psychiatry. 2016;3(3):243–250.
   Google Scholar
• Chekroud AM, Gueorguieva R, Krumholz HM, et al. Reevaluating the efficacy and predictability of antidepressant treatments: a symptom clustering approach. JAMA Psychiatry. 2017;74(4):370–378.
   Google Scholar
• Iniesta R, Malki K, Maier W, et al. Combining clinical variables to optimize prediction of antidepressant treatment outcomes. J Psychiatr Res. 2016;78:94–102.
   Google Scholar
• Kautzky A, Moller H-J, Dold M, et al. Combining machine learning algorithms for prediction of antidepressant treatment response. Acta Psychiatr Scand. 2021;143(1):36–49.
   Google Scholar
• Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83.
   Google Scholar
• Tansey KE, Guipponi M, Hu X, et al. Contribution of Kallmann genetic variants to antidepressant response. Biol Psychiatry. 2013;73(7):679–682.
   Google Scholar
• Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010;15(5):473–500.
   Google Scholar
• Perlis RH. Pharmacogenomic testing and personalized treatment of depression. Clin Chem. 2014;60(1):53–59.
   Google Scholar
• GENDEP Investigators, Mars Investigators, STAR*D Investigators. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of 3 genome-wide pharmacogenetic studies. Am J Psychiatry. 2013;170(2):207–217.
   Google Scholar
• Greden JF, Parikh WV, Rothschild AJ, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res. 2019;111:59–67.
   Google Scholar
• Bousman CA, Arandjelovic K, Mancuso SG, et al. Pharmacogenetic tests and depressive symptoms remission: a meta-analysis of randomized controlled trials. Pharmacogenomics. 2019;20(1):37–47.
   Google Scholar
• Rosenblat JD, Lee Y, McIntyre RS. The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: a meta-analysis. J Affect Disord. 2018;241:484–491.
   Google Scholar
• Zeier Z, Carpenter LL, Kalin NH, et al. Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing. Am J Psychiatry. 2018;175(9):j873–886.
   Google Scholar
• Maciukiewicz M, Marshe VS, Hauschild A-C, et al. GWAS-based machine learning approach to predict duloxetine response in major depressive disorder. J Psychiatr Res. 2018;99:62–68.
   Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382–389.
   Google Scholar
• Bao Z, Zhao X, Li J, et al. Prediction of repeated-dose intravenous ketamine response in major depressive disorder using the GWAS-based machine learning approach. J Psychiatr Res. 2021;138:284–290.
   Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62.
   Google Scholar
• Athreya AP, Neavin D, Carrillo-Roa T, et al., Pharmacogenomics-driven prediction of antidepressant treatment outcomes: a machine-learning approach with multi-trial replication. Clin Pharmacol Ther. 2019; 106(4): 855–865.
   Google Scholar
• Gupta M, Neavin D, Liu D, et al. TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics. Mol Psychiatry. 2016;21(12):1717–1725.
   Google Scholar
• Liu D, Ray B, Neavin DR, et al. Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics. Transl Psychiatry. 2018;8(1):10.
   Google Scholar
• Ji Y, Biernacka JM, Hebbring S, et al. Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics. Pharmacogenomics J. 2013;13(5):456–463.
   Google Scholar
• Rush AJ, Trivdei MH, Ibrahim HM, et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–583.
   Google Scholar
• Biernacka JM, Sangkuhl K, Jenkins G, et al. The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Transl Psychiatry. 2016;5(4):e553.
   Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40.
   Google Scholar
• Kautzky A, Baldinger P, Souery D, et al. The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression. Eur Neuropsychopharmacol. 2015;25(4):441–453.
   Google Scholar
• Souery D, Oswald P, Massat I, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multi-center study. J Clin Psychiatry. 2007;68(7):1062–1070.
   Google Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM0IV and ICD-10. J Clin Psychiatry. 1998;59(20):S22–S33.
   Google Scholar
• Lin E, Kuo P-H, Liu Y-L, et al. A deep learning approach for predicting antidepressant response in major depression using clinical and genetic biomarkers. Front Psychiatry. 2018;9:290.
   Google Scholar
• Lin E, Kuo P-H, Liu Y-L, et al. Prediction of antidepressant treatment response and remission using an ensemble machine learning framework. Pharmaceuticals. 2020;13(10):305.
   Google Scholar
• Taliaz D, Spinrad A, Barzilay R, et al. Optimizing prediction of response to antidepressant medications using machine learning and integrated genetic, clinical, and demographic data. Transl Psychiatry. 2021;11(1):381.
   Google Scholar
• Fabbri C, Corponi F, Albani D, et al. Pleiotropic genes in psychiatry: calcium channels and stress-related FKBP5 gene in antidepressant resistance. Progr Neuropsychopharmacol Biol Psychiatry. 2018;81:203–210.
   Google Scholar
• Iniesta R, Hodgson K, Stahl D, et al. Antidepressant drug-specific prediction of depression treatment outcomes from genetic and clinical variables. Sci Rep. 2018;8(1):5530.
   Google Scholar
• Uher R, Perroud N, Ng MYM, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry. 2010;167(5):555–564.
   Google Scholar
• Shumake J, Mallard JT, McGeary JE, et al. Inclusion of genetic variants in an ensemble of gradient boosting decision trees does not improve the prediction of citalopram treatment response. Sci Rep. 2021;11(1):3780.
   Google Scholar
• Bi Y, Ren D, Guo Z, et al. Influence and interaction of genetic, cognitive, neuroendocrine and personalistic markers to antidepressant response in Chinese patients with major depression. Progr Neuropsychopharmacol Biol Psychiatry. 2021;104:110036.
   Google Scholar
• Pei C, Sun Y, Zhu J, et al. Ensemble learning for early-response prediction of antidepressant treatment in major depressive disorder. J Magn Reson Imaging. 2020;52(1):161–171.
   Google Scholar
• Fabbri C, Kasper S, Kautzky A, et al. A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping. Transl Psychiatry. 2020;10(1):50.
   Google Scholar
• Lim S-W, Won -H-H, Kim H, et al. Genetic prediction of antidepressant drug response and nonresponse in Korean patients. PLoS ONE. 2014;9(9):e107098.
   Google Scholar
• Yin L, Zhang YY, Zhang X, et al. TPH, SLC6A2, SLC6A3, DRD2 and DRD4 polymorphisms and neuroendocrine factors predict SSRIs treatment outcome in the Chinese population with major depression. Pharmacopsychiatry. 2015;48(3):95–103.
   Google Scholar
• Joyce JB, Grant CW, Liu D, et al. Multi-omics drive predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication. Transl Psychiatry. 2021;11(1):513.
   Google Scholar
• Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long term outcomes of a single-blind randomized study. Am J Psychiatry. 2011;168(7):689–701.
   Google Scholar
• Bhattacharyya S, Dunlop BW, Mahmoudiandehkordi S, et al. Pilot study of metabolomic clusters as state markers of major depression and outcomes to CBT treatment. Front Neurosci. 2019;13:926.
   Google Scholar
• Mahmoudiandehkordi S, Ahmed AT, Bhattacharyya S, et al. Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. Transl Psychiatry. 2021;11(1):153.
   Google Scholar
• Czysz AH, South C, Gadad BS, et al. Can targeted metabolomics predict depression recovery? Results from the CO-MED trial. Transl Psychiatry. 2019;9(1):11.
   Google Scholar
• Perna G, Grassi M, Caldirola D, et al. The revolution of personalized psychiatry: will technology make it happen sooner? Psychol Med. 2018;48(5):705–713.
   Google Scholar
• Fernandes BS, Williams LM, Steiner J, et al. The new field of ‘precision psychiatry. BMC Med. 2017;15(1):80.
   Google Scholar
• Ritchie MD, Holzinger ER, Li R, et al. Methods of integrating data to uncover genotype-phenotype interactions. Nat Rev Genetics. 2015;16(2):85–97.
   Google Scholar
• Bzdok D, Meyer-Lindenberg A. Machine learning for precision psychiatry: opportunities and challenges. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018;3:223–230.
   Google Scholar
• Athreya A, Iyer R, Neavin D, et al. Augmentation of physician assessments with multi-omics enhances predictability of drug response: a case study of major depressive disorder. IEEE Comput Intell Mag. 2018;13(3):20–31.
   Google Scholar
• The Lancet Respiratory Medicine. Opening the black box of machine learning. Lancet Respir Med. 2018;6(11):801.
   Google Scholar
• Chen JH, Asch SM. Machine learning and prediction in medicine – beyond the peak of inflated expectations. N Engl J Med. 2017;376(26):2507–2509.
   Google Scholar
• Porcelli S, Drago A, Fabbri C, et al. Pharmacogenetics of antidepressant response. J Psychiatry Neurosci. 2011;36(2):87–113.
   Google Scholar
• Mirza B, Wang W, Wang J, et al. Machine learning and integrative analysis of biomedical big data. Genes (Basel). 2019;10(2):87.
   Google Scholar
• Reel PS, Reel S, Pearson E, et al. Using machine learning approaches for multi-omics data analysis: a review. Biotechnol Adv. 2021;49:107739.
   Google Scholar
• Dantzer, O’Connor JC, Lawson MA, et al. Inflammation-associated depression: from serotonin to kynurenine. Dantzer R, O’Connor JC, Lawson MA, et al. Psychoneuroendocrinology. 2011;36(3):426–436.
   Google Scholar
• Lam RW, Milev R, Rotzinger S, et al. Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. BMC Psychiatry. 2016;16(1):105.
   Google Scholar
• Menke A, Weber H, Deckert J. Roadmap for routine pharmacogenetic testing in a psychiatric university hospital. Pharmacopsychiatry. 2020;53(4):179–183.
   Google Scholar
• Wang L, Scherer SE, Bielinski SJ, et al. Implementation of preemptive DNA sequence-based pharmacogenomic testing across a large academic medical center: the Mayo-Baylor RIGHT 10K Study. Genet Med. 2022;24(5):1062–1072.
   Google Scholar
• Fatumo S, Chikowore T, Choudhury A, et al. A roadmap to increase diversity in genomic studies. Nat Med. 2022;28(2):243–250.
   Google Scholar
• McIntyre RS, Lee Y, Mansur RB. Treating to target in major depressive disorder: response to remission to functional recovery. CNS Spectr. 2015;20(S1):20–30.
   Google Scholar
• Dietterich T. Overfitting and undercomputing in machine learning. ACM Comput Surv. 1995;27(3):326–327.
   Google Scholar
• Hofman JM, Watts DJ, Athey S, et al. Integrating explanation and prediction in computational social science. Nature. 2021;595(7866):181–188.
   Google Scholar
• Aradhya S, Nussbaum RL. Genetics in mainstream medicine: finally within grasp to influence healthcare globally. Mol Genet Genomic Med. 2018;6(4):473–480.
   Google Scholar
• Cameron LD, Muller C. Psychosocial aspects of genetic testing. Curr Opin Psychiatry. 2009;99(2):218–223.
   Google Scholar
• Johansen Taber KA, Dickinson BD. Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties. Pharmacogenomics Pers Med. 2014;7:145–162.
   Google Scholar
• Selkirk CG, Weissman SM, Anderson A, et al. Physicians’ preparedness for integration of genomic and pharmacogenetic testing into practice within a major healthcare system. Genet Test Mol Biomarkers. 2013;17(3):219–225.
   Google Scholar
• Stanek EJ, Sanders CL, Frueh FW. physician awareness and utilization of food and drug administration (FDA)-approved labeling for pharmacogenomic testing information. J Pers Med. 2013;3(2):111–123.
   Google Scholar
• Stanek EJ, Sanders CL, Taber KAJ, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther. 2012;91(3):450–458.
   Google Scholar
• Salm M, Abbate K, Appelbaum P, et al. Use of genetic tests among neurologists and psychiatrists: knowledge, attitudes, behaviors, and needs for training. J Genet Couns. 2014;23(2):156–163.
   Google Scholar
• Thompson C, Steven PH, Catriona H. Psychiatrist attitudes towards pharmacogenetic testing, direct-to-consumer genetic testing, and integrating genetic counseling into psychiatric patient care. Psychiatry Res. 2015;226(1):68–72.
   Google Scholar
• Walden LM, Brandl EJ, Changasi A, et al. Physicians’ opinions following pharmacogenetic testing for psychotropic medication. Psychiatry Res. 2015;229(3):913–918.
   Google Scholar
• Jacobs M, Pradier MF, McCoy TH, et al. How machine-learning recommendations influence clinician treatment selections: the example of antidepressant selection. Transl Psychiatry. 2021;11(1):108.
   Google Scholar
• Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–46.
   Google Scholar